bulevirtide acetate: clinical use

Prescribing considerations

• Initiation should be by a physician experienced in managing HDV infection.
• Confirm detectable HDV RNA and compensated liver disease; use in decompensated disease is not recommended.
• Manage underlying hepatitis B concurrently and review HBV antiviral requirements.
• Evidence is limited in renal impairment, older people and people co-infected with HIV or hepatitis C.
• Paediatric licensing is supported by pharmacokinetic and pharmacodynamic modelling rather than clinical efficacy trials in children.

Contraindications and cautions

• Hypersensitivity to bulevirtide or any excipient.

Monitoring

• Assess clinical, biochemical and virological response, including liver tests and HDV RNA.
• Monitor HBV DNA because underlying hepatitis B remains clinically relevant.
• Monitor renal function carefully; bile-salt elevations may be greater with renal impairment.
• After discontinuation, continue clinical and laboratory follow-up for HDV/HBV reactivation and hepatitis flare.

Clinical pharmacology

Bulevirtide is a synthetic peptide entry inhibitor that binds and inactivates NTCP. It is highly protein-bound, is expected to break down into smaller peptides and amino acids, and has no expected active metabolites.

Formulation and product differences

• The UK product is a white to off-white powder in a single-use vial requiring reconstitution with sterile water before subcutaneous injection.
• Injection supplies and sterile water are not contained in the medicine carton.
• The prepared solution should be clear and used immediately where possible; unopened vials require refrigerated, light-protected storage.
• The formulation is essentially sodium-free.

Injection

Route: Parenteral

Strengths: 2 mg